Pfizer, COVID-19 and Health Canada
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal.
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.
Pfizer and BioNTech’s Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive EU Opinion, Awaiting Approval
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA)
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus.
Pfizer, BioNTech's Omicron-Adapted Covid-19 Vaccine Gets E.U. Marketing Recommendation
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is one step closer to becoming available across the European Union.
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
STAT1d
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer and its partner, BioNTech, sued Moderna in London in September 2022, seeking to revoke two patents held by Moderna ...
Pfizer’s Solid Fundamentals and Strategic Acquisitions Affirm Buy Rating Despite Oxbryta Setback
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report), retaining the price target of $36.00.
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
BBC3y
Covid-19: Pfizer/BioNTech vaccine judged safe for use in UK
The UK has become the first country in the world to approve the Pfizer/BioNTech coronavirus vaccine, paving the way for ...
Pfizer’s Stock Faces Challenges as Oxbryta Recall Impacts Drug Pipeline and Financial Projections
Pfizer (PFE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
Time on MSN3d
Is the Novavax COVID-19 Vaccine Better?
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another ...
Pfizer withdraws sickle cell drug Oxbryta over safety concerns
Pfizer (PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety ...
Pfizer’s Investment Outlook: A Cautious Hold Amid Oxbryta Withdrawal and Mixed Acquisition Results
In a report released today, Carter Gould from Barclays maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of ...